AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12752317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg bid everolimus
Number of subjects: 731
Study 12752317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg bid everolimus
Number of subjects: 731
Study 12752317 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall everolimus exposure
Number of subjects: 731
Study 10337871 — intervention group
Group type: EXPERIMENTAL
Intervention: DG/EE formulation
Number of subjects: 21
Study 10337871 — intervention group
Group type: EXPERIMENTAL
Intervention: LN/EE formulation
Number of subjects: 21
Study 7856893 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/nitrous oxide
Number of subjects: 112
Study 7856893 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane/nitrous oxide
Number of subjects: 112
Study 1827560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil and leucovorin
Number of subjects: 0
Study 7408407 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bretylium tosylate (5 mg/kg)
Number of subjects: 10
Study 7408407 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bretylium tosylate (5 mg/kg)
Number of subjects: 10
Study 31170543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating mesh nebulizer (VMN)
Number of subjects: 9
Study 31170543 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer (JN)
Number of subjects: 9
Study 27296626 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week oral language programme delivered by trained teaching assistants
Number of subjects: 104
Study 27296626 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 104
Study 25306247 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-Avoidance Task (AAT) - standard version
Number of subjects: 257
Study 25306247 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-Avoidance Task (AAT) - individual feedback version
Number of subjects: 257
Study 25306247 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 257
Study 21816640 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ATN-224 (30 mg daily)
Number of subjects: 47
Study 21816640 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ATN-224 (300 mg daily)
Number of subjects: 47
Study 21640687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime cilnidipine (10-20 mg/day)
Number of subjects: 43
Study 21640687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (morning or bedtime)
Number of subjects: 43
Study 18701184 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (Diet I)
Number of subjects: 204
Study 18701184 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (Diet II)
Number of subjects: 204
Study 16530955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepulse + Pulse trials with 60, 120, and 240 ms prepulse-pulse intervals
Number of subjects: 19
Study 16530955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepulse + Pulse trials with 60 and 120 ms prepulse-pulse intervals
Number of subjects: 19
Study 16530955 — intervention group
Group type: COMPARATOR
Intervention: Pulse-Alone trials
Number of subjects: 19
Study 16530955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepulse + Pulse trials
Number of subjects: 19
Study 12657911 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic reboxetine (6-month monotherapy)
Number of subjects: 47
Study 12657911 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic reboxetine (therapeutic drug monitoring)
Number of subjects: 47
Study 11084270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% administered 30 minutes preoperatively
Number of subjects: 48
Study 11084270 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac tromethamine 0.5% administered 1 day postoperatively
Number of subjects: 48
Study 1384423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (1 g)
Number of subjects: 25
Study 1384423 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (30 mg/kg)
Number of subjects: 25
Study 1384423 — intervention group
Group type: COMPARATOR
Intervention: Healthy Volunteer Subjects (HVS) receiving vancomycin (1 g)
Number of subjects: 25
Study 4050068 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 120
Study 4050068 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole (ASA-D)
Number of subjects: 120
Study 4050068 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation with coumadine preparations (AC)
Number of subjects: 120
Study 31880109 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care ultrasound oriented treatment
Number of subjects: 147
Study 31880109 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 147
Study 31880109 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 147
Study 31880109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake during salvage and optimization phases
Number of subjects: 147
Study 31880109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake during stabilization and de-escalation phases
Number of subjects: 147
Study 30053670 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin with paclitaxel (Arm C)
Number of subjects: 76
Study 30053670 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin with pemetrexed (Arm D)
Number of subjects: 76
Study 30053670 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin with nab-paclitaxel (Arm E)
Number of subjects: 76
Study 27411096 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) before PCI procedures
Number of subjects: 46
Study 27411096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 46
Study 24591296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal douche containing 9 mg of high molecular weight sodium hyaluronate plus saline solution
Number of subjects: 124
Study 24591296 — intervention group
Group type: COMPARATOR
Intervention: Saline solution alone
Number of subjects: 124
Study 22137609 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated pharmaceutical care programme (IPCP)
Number of subjects: 238
Study 22137609 — intervention group
Group type: COMPARATOR
Intervention: Normal follow-up (Control)
Number of subjects: 238
Study 20413273 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the lobular branch of GAN (group C)
Number of subjects: 93
Study 20413273 — intervention group
Group type: COMPARATOR
Intervention: Sacrifice of the main trunk of GAN (group A)
Number of subjects: 93
Study 20413273 — intervention group
Group type: COMPARATOR
Intervention: Preservation of the posterior-auricular branch (group B)
Number of subjects: 93
Study 18568078 — intervention group
Group type: EXPERIMENTAL
Intervention: twice daily subcutaneous injections of leptin
Number of subjects: 6
Study 18568078 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 16082018 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak net joint moment (PM) during Work task
Number of subjects: 18
Study 16082018 — intervention group
Group type: EXPERIMENTAL
Intervention: Average net joint moment (AM) during Work task
Number of subjects: 18
Study 16082018 — intervention group
Group type: EXPERIMENTAL
Intervention: Net joint moment impulse (IP) during Work task
Number of subjects: 18
Study 16082018 — intervention group
Group type: EXPERIMENTAL
Intervention: Average net joint moment (AP) during Power task
Number of subjects: 18
Study 16082018 — intervention group
Group type: EXPERIMENTAL
Intervention: Net joint moment impulse (IM) during Power task
Number of subjects: 18
Study 16082018 — intervention group
Group type: EXPERIMENTAL
Intervention: All 6 measures during Work task
Number of subjects: 18
Study 11860966 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens (SCL) wear for 3 hours
Number of subjects: 20
Study 11860966 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral eye without SCL)
Number of subjects: 20
Study 10068153 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg daily for 4 days
Number of subjects: 12
Study 10068153 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin 600 mg daily for 5 days
Number of subjects: 12
Study 8882243 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam 20 mg plus ondansetron 8 mg
Number of subjects: 24
Study 8882243 — intervention group
Group type: COMPARATOR
Intervention: temazepam 20 mg plus placebo
Number of subjects: 24
Study 1733176 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg three times daily for 10 days
Number of subjects: 231
Study 1733176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 6395920 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Subgroup O)
Number of subjects: 223
Study 6395920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Tamoxifen (Subgroup N)
Number of subjects: 223
Study 6395920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Tamoxifen + Norethisterone (Subgroup NN)
Number of subjects: 223
Study 6395920 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Group I)
Number of subjects: 223
Study 6395920 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Group II)
Number of subjects: 223
Study 31782009 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvianolate
Number of subjects: 318
Study 31782009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 28961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Slide Imaging (WSI)
Number of subjects: 1992
Study 28961557 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 1992
Study 28961557 — intervention group
Group type: COMPARATOR
Intervention: Comparison of WSI and Microscopy
Number of subjects: 1992
Study 28961557 — intervention group
Group type: EXPERIMENTAL
Intervention: WSI in endocrine pathology
Number of subjects: 1992
Study 28961557 — intervention group
Group type: EXPERIMENTAL
Intervention: WSI in neoplastic kidney pathology
Number of subjects: 1992
Study 28961557 — intervention group
Group type: EXPERIMENTAL
Intervention: WSI in urinary bladder pathology
Number of subjects: 1992
Study 28961557 — intervention group
Group type: EXPERIMENTAL
Intervention: WSI in gynecologic pathology
Number of subjects: 1992
Study 27211289 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient centered pathology report
Number of subjects: 40
Study 27211289 — intervention group
Group type: COMPARATOR
Intervention: Standard report
Number of subjects: 40
Study 25543614 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-play simulation
Number of subjects: 32
Study 25543614 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning
Number of subjects: 32
Study 22170790 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking skill training program (12 sessions of weight-bearing activities)
Number of subjects: 68
Study 19814835 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral supplement containing glutamine and antioxidants
Number of subjects: 21
Study 19814835 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 21
Study 17211866 — intervention group
Group type: EXPERIMENTAL
Intervention: IA carboplatin with intravenous etoposide and cyclophosphamide
Number of subjects: 38
Study 17211866 — intervention group
Group type: EXPERIMENTAL
Intervention: IA methotrexate with intravenous etoposide and cyclophosphamide
Number of subjects: 38
Study 16246231 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day high-dose quadruple therapy (esomeprazole 40 mg b.i.d., colloidal bismuth subcitrate 440 mg q.i.d., amoxicillin 2 g q.i.d., metronidazole 400 mg q.i.d. for 1 day)
Number of subjects: 80
Study 16246231 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy (esomeprazole 20 mg b.i.d., clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. for 7 days)
Number of subjects: 80
Study 16246231 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day high-dose quadruple therapy
Number of subjects: 80
Study 16246231 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy
Number of subjects: 80
Study 12171809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline, 75 mg/d for 6 weeks
Number of subjects: 144
Study 12171809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 9949712 — intervention group
Group type: EXPERIMENTAL
Intervention: Models used to convey spatial knowledge
Number of subjects: 0
Study 9949712 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagrams used to convey spatial knowledge
Number of subjects: 0
Study 9949712 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagrams with rich pictorial depth cues
Number of subjects: 0
Study 9949712 — intervention group
Group type: EXPERIMENTAL
Intervention: Models viewed without access to depth cues
Number of subjects: 0
Study 7758327 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.1 mg/ml) administered via subcutaneous injections or by scratching at the site of patch tests
Number of subjects: 28
Study 7758327 — intervention group
Group type: COMPARATOR
Intervention: Control solution administered immediately before patch testing (0 hours) or 2x at 0 and 24 h
Number of subjects: 28
Study 1869364 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg x 3 days
Number of subjects: 66
Study 1869364 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 1200 mg x 2 days
Number of subjects: 66
Study 1869364 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 1200 mg x 3 days
Number of subjects: 66
Study 1869364 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg x 2 days
Number of subjects: 66
Study 1869364 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg x 1 day
Number of subjects: 66
Study 1869364 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg x 1 day
Number of subjects: 66
Study 1869364 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabrine 1.2 g per case for males and 1.0 g per case for females (re-treatment after 3 months)
Number of subjects: 66
Study 7164524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation
Number of subjects: 13
Study 7164524 — intervention group
Group type: COMPARATOR
Intervention: Control group (without ultraviolet radiation)
Number of subjects: 13
Study 31960188 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating patient's information into surgical videos
Number of subjects: 130
Study 31399143 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 3
Study 31399143 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 3
Study 31399143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 27921200 — intervention group
Group type: EXPERIMENTAL
Intervention: Food, Health & Choices (FHC) intervention taught by trained FHC instructors
Number of subjects: 20
Study 27921200 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher interest
Number of subjects: 20
Study 27921200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity
Number of subjects: 20
Study 27210726 — intervention group
Group type: EXPERIMENTAL
Intervention: Online depression intervention
Number of subjects: 58
Study 27210726 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 58
Study 24387891 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 28
Study 24387891 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 28
Study 24387891 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic comparison group
Number of subjects: 28
Study 23785922 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia (M)
Number of subjects: 72
Study 23785922 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-articular injection (I)
Number of subjects: 72
Study 23785922 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (P)
Number of subjects: 72
Study 20329616 — intervention group
Group type: EXPERIMENTAL
Intervention: Corydalis composite (CDC) combined with methotrexate (MTX)
Number of subjects: 76
Study 20329616 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 76
Study 17584432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care according to the Roper, Logan and Tierney Model
Number of subjects: 60
Study 17584432 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 60
Study 15641626 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily budesonide administration
Number of subjects: 5998
Study 12469466 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 181
Study 12469466 — intervention group
Group type: COMPARATOR
Intervention: Mini‐cholecystectomy
Number of subjects: 181
Study 9797101 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐mm microlaparoscope (MicroLap)
Number of subjects: 135
Study 9797101 — intervention group
Group type: COMPARATOR
Intervention: 10‐mm standard laparoscope
Number of subjects: 135
Study 7707626 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent vaccine
Number of subjects: 1006
Study 7707626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine
Number of subjects: 1006
Study 2798994 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 48
Study 2798994 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 48
Study 87093 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic retinoid ethyl ester (Ro 10‐9359)
Number of subjects: 19
Study 87093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31856991 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5 PRO OVD (bacterially derived sodium hyaluronate 2.3%)
Number of subjects: 421
Study 31856991 — intervention group
Group type: COMPARATOR
Intervention: Healon5 OVD (animal-derived sodium hyaluronate 2.3%)
Number of subjects: 421
Study 31856991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OVDs
Number of subjects: 421
Study 28340572 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg, maximum 20 mg) and oral ketamine (3 mg/kg, maximum 50 mg) with 100% oxygen (MK)
Number of subjects: 27
Study 28340572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg, maximum 20 mg) and oral ketamine (3 mg/kg, maximum 50 mg) with inhalational sevoflurane at a sedative dose (MKS)
Number of subjects: 27
Study 28340572 — intervention group
Group type: EXPERIMENTAL
Intervention: MKS
Number of subjects: 27
Study 28340572 — intervention group
Group type: COMPARATOR
Intervention: MK
Number of subjects: 27
Study 24983382 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 120
Study 24983382 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 120
Study 23726660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management intervention
Number of subjects: 325
Study 23726660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive coping strategies (acceptance and positive reframing)
Number of subjects: 325
Study 23109026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal liver‐derived hematopoietic stem cell transplantation
Number of subjects: 56
Study 23109026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml of normal saline via intravenous route)
Number of subjects: 56
Study 19535188 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced euvolemic diuresis with saline, mannitol, and furosemide
Number of subjects: 92
Study 19535188 — intervention group
Group type: COMPARATOR
Intervention: Saline hydration (control)
Number of subjects: 92
Study 19535188 — intervention group
Group type: COMPARATOR
Intervention: Overall (meta-analysis of 3 trials)
Number of subjects: 92
Study 17405800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVTA) injections
Number of subjects: 27
Study 15082356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled intranasal (PCIN) fentanyl
Number of subjects: 26
Study 15082356 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 26
Study 11438054 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser scanning tomography with clinical optic disk photographs
Number of subjects: 16
Study 11438054 — intervention group
Group type: COMPARATOR
Intervention: Confocal laser scanning tomography without clinical optic disk photographs
Number of subjects: 16
Study 9549663 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 48
Study 9549663 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 48
Study 9549663 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 600 mg
Number of subjects: 48
Study 9549663 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 900 mg
Number of subjects: 48
Study 9549663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8053583 — intervention group
Group type: COMPARATOR
Intervention: Soda lime as CO2 absorbent
Number of subjects: 16
Study 8053583 — intervention group
Group type: EXPERIMENTAL
Intervention: Baralyme as CO2 absorbent
Number of subjects: 16
Study 8053583 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Soda lime and Baralyme)
Number of subjects: 16
Study 8053583 — intervention group
Group type: EXPERIMENTAL
Intervention: Baralyme
Number of subjects: 16
Study 3072894 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 21
Study 3072894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg
Number of subjects: 21
Study 31909884 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinner-strut sirolimus-eluting bioresorbable scaffold (Firesorb)
Number of subjects: 45
Study 30860411 — intervention group
Group type: EXPERIMENTAL
Intervention: SVW (same volume with both legs starting with the weaker leg)
Number of subjects: 45
Study 30860411 — intervention group
Group type: EXPERIMENTAL
Intervention: DVW (double volume with the weaker leg starting with the weaker leg)
Number of subjects: 45